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Sm_mary In this study we have investigated the role of thrombospondin (TSP) as a possible ligand playing a
key role in human M3Da. melanoma cell interaction with platelets and in tumour growth. TSP is secreted
(80 ± 6 ng TSP 1O-' cells) and bound to the surface of M3Da. cells via receptors different from CD36, as
shown by biosynthetic labelling and immunofluorescence studies. The levels of TSP binding to M3Da. cells
evaluated by binding studies, using an anti-TSP monoclonal antibody (MAb) (LYP8), shows 367 000 ±58 000
(mean ± s.d.) LYP8 binding sites per cell with a dissociation constant (Kd) of 67nrM. TSP binding to M3Da.
cells shows 400000 ± 50 000 TSP binding sites per cell with a Kd of l0 nM. The capacity of anti-TSP MAb
(LYP8) to inhibit M3Da.-platelet interactions was followed on an aggregometer and evaluated by electron
microscopy studies. The biological role of TSP binding to M3Da. cells was investigated by implanting
subcutaneously the M3Da. cel line in nude mice and following the size and time of in vivo tumour growth.
Reducing the availability or the functional level of TSP by using an anti-TSP MAb (LYP8) resulted in a
significant decrease in platelet aggregates interacting with M3Da. melanoma cells. Using an enzyme-linked
immunosorbent assay, purified eA was shown to bind TSP. Moreover, LYP8-coated M3Da. cells showed a
reduced capacity to form tumours in vivo. M3Da. cells were observed to attach and spread on human platelet
TSP-coated plastic wells. This attachment by M3Da. cells was inhibited in a similar way by LYP8 and an
anti-oc3 MAb (LYP18). The results obtained in this study show that TSP secreted and bound to the surface
of a human melanoma cell line (M3Da.) acts as a link between aggregated platelets and the M3Da. cell surface.
Moreover, these results shows that TSP can modulate tumour growth in vivo. Reagents such as MAbs directed
against TSP and peptides derived from TSP could not only be used as a new therapeutic approach in the
control of tumour metastasis ofmelanoma, but may also contribute to elucidation ofthe role ofTSP in cancer
biology.
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Thrombospondin (TSP) is a high molecular weight (450 kDa)
glycoprotein (GP) that is released from the a-granules of
platelets during activation (Lawler, 1986). In the presence of
a physiological concentration of calcium, TSP binds to the
surface of stimulated platelets and plays an active role in
promoting platelet aggregation (Leung, 1984; Boukerche and
McGregor, 1988; McGregor and Boukerche, 1993). TSP is
also secreted by a variety of cells, such as pneumocytes,
endothelial cells, macrophages, fibroblasts, smooth muscle
cells, chondrocytes and mesangial cells, as well as by a
number of tumour cell lines, including melanomas and car-
cinomas (Varani et al., 1986, 1989). In addition to its role in
blood coagulation, TSP has been reported to promote
adhesion and motility of several of these cell types (Walz,
1992). Released TSP will bind to the surface of activated
platelets or cells via a number of glycoprotein receptors, such
as the integrins GPIIb-IIIa (oEA,) and m2p, (Karczewski et
al., 1989; Tuszynski and Kowalska, 1991), the vitronectin
receptor a, (Lawler et al., 1988), GPIV (also called CD36)
(Asch et al., 1987; McGregor et al., 1989), the integrin-like
receptor (105/80 kDa) (Yabkowitz and Dixit, 1991) and the
heparan sulphate proteoglycans (Roberts, 1988). Recently, it
was shown that tumour formation and the metastatic spread
of lung tumours in mice was increased by TSP and was
significantly reduced by use of TSP peptide CSVTCG or a
TSP cDNA antisense expression vector (Tuszynski et al.,
1987, 1992; Castle et al., 1991). These studies suggest that
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TSP plays a major role in cell adhesion and cell-cell interac-
tions in the metastatic process.
However, so far very little is known about the precise
biological role of TSP in tumour-platelet interactions and
tumour cell growth. Moreover, the identity of the TSP recep-
tor(s) mediating tumour cell-platelet interactions and
tumour growth remains to be elucidated. We have previously
reported that a monoclonal antibody (LYP18), generated
against human blood platelet glycoprotein lIb-Illa (muA),
immunoprecipitated two proteins from a tumorigenic human
melanoma cell line (M3Da.) immunologically related to the
vitronectin receptor (a,3) (Boukerche et al., 1989a,b). When
bound to the melanoma cell surface, LYP18 dramatically
inhibited melanoma-platelet interactions and the growth of
melanoma cells in nude mice. However, at that stage of our
work we had not yet investigated possible ligands involved
link-ing M3Da. receptors, such as mA, and platelets or the
basement membrane extracellular matrix (ECM) com-
ponents. Results presented in this study show that TSP
secreted and bound to the surface of a human melanoma cell
line (M3Da.) acts as a link between aggregated platelets and
the M3Da. cell surface. Moreover, these results show that
TSP can modulate tumour growth in vivo.
Materis and methods
Antibodies
Monoclonal antibody (MAb) LYP8 was produced in our
laboratory and was previously shown by crossed
immunoelectrophoresis and affinity chromatography to be
directed against platelet thrombospondin 1 (TSP1). It recog-
nises a determinant associated with the intact conformation
of the antigen, since it failed to bind to a Western blot of
SDS-electrophoresed TSP (Boukerche and McGregor, 1988)._s-c mIA
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No difference in the binding of LYP8 to TSP in an enzyme-
inked immunosorbent assay (ELISA) could be observed in
the presence of 2 mM ma2 + or 5 mM EDTA. The LYP8
epitope lies within the 140 kDa non-heparin biing frag-
ment. LYPIO and LYP12 anti-TSP MAbs were produced in
our laboratory and are respectively direted against the
70 kDa trypsin-resistant core region and the hin-binding
domain ofTSP1 (Catimel et al., 1992). An anti-GPHTb MAb
(OKM5) was a generous gift from Ortho Pharmaceutical.
MAb G7A5 dircd against a melanoma cell membrane
antigen was purchased from Immunotech.
Twnour cells
The M3Da. (= M3Dau.) cell line was established from an
achromic skin metastasis of a patient with malignant
melanoma (Jacubovitch et al., 1984). The cells were cultured
as monolayers in RPMI-1640 supplemented with 10% fetal
bovine serum and have a doubling time of 28 h (Boukerce
et al., 1989a). Cultures were routinely checked and found to
be free of mycoplasma, using the Hoechst 33258 fluorescence
stining procedure. Cell monolayers, used in platelet aggrega-
tion studies, were detac by EDTA and ressended in
HBSS (Hankrs' balanced salt solution) containing 0.2% calf
serm albumin (BSA) as previously descibed (Boukerche et
al., 1989a). Cell viability, asesed by trypan blue exclusion,
was consistetly 95% throughout the experients.
Immunofluorescence studies on these cells were performed as
follows: cells were gently washed three times with Ca2+/
Mg2+-free HBSS, detached with EDTA and resspended in
phosphate-buffered saline (PBS), pH 7.2. The cells were then
incubated initially with a 1:50 dilution of the monoclonal
antibody LYP8, LYP18 or OKM5 for 30 min at room
temperature. Cells were washed with PBS, pH 7.2, and
stained for 30min with a 1:50 dilution of fluorescein-
conjuguated goat anti-(mouse IgG) F(ab%. Following three
additional washes in PBS, pH 7.2, cells were analysed by
standard fluorescence microscope te:chniques.
Effect ofan anti-TSP MAb (LYP8) on melanoma-platelet
interaction
Blood from healthy donors was drawn into heparin
anticoagulant and centrifiged at 160 g for 20min to obtain
platelet-rich plasma (PRP). Aggregation studies were per-
formed with platelets in PRP adjusted to 3 x 10' cells ml-'
and melanoma cells preincubated for 1 h at 3TC before
addition to 0.4 ml of PRP (Boukerche et al., 1989a).
Melanoma cells (4 x 10' cells) were preincubated with
saturating concentrations of LYP8 (24 pg 10-' cells) or
LYP18 (14 pg 10-6 cells), washed three times with HBSS
containing 0.2% BSA then added to PRP. Platelet aggrega-
tion by melanoma cells was quantified by measuring the peak
height of the aggregation curve as previously described
(Boukerche et al., 1989a).
Electron microscopy ofplatelet-melanoma interaction
At the end of the aggregation curve, platelet-mnlanoma
suspensions were fixed with 0.15% glutardehyde in 0.1
mol I' cacodylate buffer and then filtered through 0.22 pm
filters (Millpore, France). The fixed material was processed
for electron microscopy as previously described using a
Siemens ELM 102 transmission electron microscope (Bouker-
che et al., 1989a).
Immunoprecipitation
Confluent melanoma cells were metabolcaBlly labelled with
I'S for 24h and chased for 18 h in the absence of labelled
methionine. The Triton X-100-extracted melana chase
media were immunoprecipitated with an anti-TSP MAb
(LYP8) or a non-immune mouse serum IgG and analysed by
sodium dodecyl sulphate-polyacrylamide gel eectrophoresis
(SDS-PAGE) as previously described (Boukerche et al.,
1989b).
Isolation ofthrombospondn and vitronectin receptors
Thrombospondin (TSP) was purified from the superatant of
ionophore-actiated human platelets on a heparin-Sepharose
CL-6B column in the presence of2 mm calcium following the
method of Lawler et al., (1988). Vitronectin receptor (VnR)
was isolated from melanoma cells by LYP18-affinity chroma-
tography as previously described (Boukerche and McGregor,
1988). The VnR was more than 95% pure when analysed by
SDS-PAGE.
Bindng studies
Human melanoma cells grown to confluence in serum-free
RPMI were detached from culture plates by brief treatment
with trypin-EDTA and ressended in RPMI-1640 con-
taining 0.35% BSA_ Thrombospondin (TSP) or isolated
antibody was labelled with 'lI as previously described
(Boukerche and McGregor, 1988). Labelled TSP or antibody
was separated from free '2I on a PD-10 column (Sephadex
G-25 M). Increasing concentrations of '25I-labelled TSP
(0.4-24pg ml-') or '25I-labelled LYP8 (0.4-24 pg ml-) were
added to 10' cells and incubated overnight at 4C. At the end
of the incubation time, aliquots of the melanoma-antibody
or melanoma-TSP mixture were layered in tripliate in
400p1 Eppendorf tubes contining 20% sucrose, 2% bovine
serun albumin prepared in PBS, pH 7.2. The amount for
'WI-labelled TSP or "5I-labelled LYP8 bound per melanoma
cell was determined by counting the radioactivity of the
cut-offcentrifuge tips. Non-specific binding was measured by
incubating cells with a 100-fold excess of unlabeled TSP or
monoclonal antibody. This non-specific binding (less than
10-15%) was subtracted from the total binding. The number
of binding sites per cell and the dissociation constant were
obtained by double-reciprocal plots and least-squares regres-
sion analyis. The valus reported are the mean of three
expeiments. Binding of TSP to vitronectin receptor was
studied using an ELISA as described previously (Boukerche
and McGregor, 1988). Briefly, purified 3 (2-3pg) diluted
in PBS, pH 7.2, contaig 2mM calcium chloride was
adsorbed on each well of the microtitre plate for overnight
incubation at 4C. Wells were then washed in PBS containing
1 mM calcium chloride supplemented with 0.05% Tween 20,
and inraeasing concentrations of TSP or albumin
(0.1-1.5pg) diluted in PBS containing 2 mM calcium
chloride were added to wells for ovemight incubation at 4C.
Plastic wells were then washed and anti-TSP polyclonal
antibody was added for I h at 37C to detect bound TSP.
After additional washes, goatanti-rabbit antibody conjugated
to horseradish peroxidase was added and bound anti-TSP
polyclonal antibody was quantified by the addition of the
substrate orthophenydiethylanine.
Quantiication by ELISA ofsecreted thrombospondn by
melanoma cells
Melanoma cells in complete medium were plated at 3.5 x 109
cells per well and grown for 1 day. The cells were then
extnsively washed with serum-free RPMI and incubated for
6 h in serum-free RPMI containing 0.2% BSA. Cells were
centrfuged at 200g for 10min at 4-C and TSP secreted into
the culture medium was assayed as previously descnrbd
(Riser et al., 1988) usng a TSP ELISA kit (Stago, France).
Cell adhesion assays
The cell adhesion assay was performed as previously des-
cribed (Varani et al., 1986). Briefly, 2-3 pg of TSP or BSA
diluted in PBS, pH 7.2, containing 1 mm cacium chloride
and 0.5 mM magnesum chloride was adsorbed on each wel
of the microtitre plate for 1 h at 3TC. After washing, the
wells were blocked with serum-free minimum esential
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medium (MEM) supplemented with 0.2% BSA to minimise
non-specific tumour cell adhesion. Anti-TSP MAb (LYP8)
was then added to the wells and incubated for 20 min at
3TC. Melanoma cells were briefly harvested from culture by
trypsinisation or by replacing the medium with PBS, pH 7.2,
containing 2.5 mm EDTA, washed in serum-free MEM and
resuspended in serum-free MEM co iing 0.2 mgml-1
BSA. Cells (10') were then added to coated wells for
60-90 min at 37C. After gently washing, wells were then
fixed with glutaraldehyde and stained with 1.5% Giemsa
Attached and spread cells were counted microscopically. In
other experiments, cells were preincubated for 20min at 3TC
with anti-4a MAb (LYP18) (14pg 10-') before being added
to TSP-coated wells. Cells adhering to albumin-coated wells
were not significnt (less than 2%) compared with cells
adhering to TSP-coated wells.
Tumorigenicity assays
Melanoma cells were harvested by trypinisation and washed
three times with serum-containing medium, then reuspened
in PBS, pH 7.2. Two hundred microlitres of M3Da. cells
(1 x 10') were grafted subcutaneously (s.c.), as previously
described (Boukerche et al., 1989b), on the ventral surface of
nude mice, after preincubation for 20min with purified
LYP8 (24pg 10'-), LYP18 (7pg 10-'), a non-immune mouse
serum IgG or G7A5 (directed ast a melanoma cell-surface
antigen other than the vitronectin receptor ma or thrombos-
pondin). Tumour sies at different time points were expressed
as the mean of the sum of two perpendicular diameters. In
these experiments, five mice were used for each time point.
Assaysfor effect ofLYP8 on tumour cellproliferation and
nucleic acidsynthesis
Tumour cell proliferation Aliquots (6.5 x 104) of melanoma
cell suspension preincubated for 10min at room temperature
with a saturating concentration of MAb LYP8 (24pg 10-6)
or a non-immune mouse serum IgG were seeded to each of
the %wels of the flat-bottomed tissue culre plate. At
sected time, cells were washed with Dulbecco's PBS, tryp-
sinised and counted. Data are the mean of si well counts.
Nucleic acid synthesis Aliquots (15 x 103) of melanoma cell
suspenson preincubated with saturatng concentration of
MAb LYP8 (24pg 10-') or a non-immune mouse serum IgG
were added to each ofthe 24wells ofthe flat-bottomed tisse
culture plate and cultured for 1-2 days. The ceils in each
well were pulsed for 12 h with [H]thymidine (0.0185 MBq
per well, 37 GBq mmol-', Amersham). Cells were then
washed with Dulbecco's PBS, typsinised and radioactivity
incorporated in the cells counted. Data are the mean of 12
well counts.
Resds
Cell-surface expression ofthrombospondi (TSP) by M.Da.
An ELISA, performed on the conditioned media of cultured
cells, showed that M3Da. secreted 80 ± 6ng TSP 10-6 cells
(mean ± s.d., n = 3). LYP8, a monoclonal antibody (MAb)
directed against platelet TSP and a potent inhibitor of
platet aggregation induced by thrombin and collagen
(Boukerche and McGregor, 1988), immunoprecipitated from
chase media of metabolically labeLled M3Da. melanoma cells
a protein having the same apparent molecular weight (mol.
wt) as TSP with the characterstic changes in mobility on
reduction (Figure la). This MAb was observed by
immunoluorescence staining to bind to the surface ofM3Da.
melanoma ceis (Figure lb). T-his staining appeared uniformly
distributed over the entire surface of M3Da cells, with high
fluoresnce intensity in some areas ofthe membrane, sugges-
ting the presence of csters of TSP. Altematively, this
clustering may be an artefact due to multivalent interaction
of the first antibody with cell-surface TSP. Similarly, as
previously reported, M3Da. cells stained with an anti-aA
MAb LYP18 (Figure lb) (Boukerche et al., 1989b). In con-
trast, an anti-CD36, polyclonal or MAb OKM5, did not
bind to M3Da cells (Figure lb). To determine the number of
TSP molecules expressed on the surface of melanoma cells,
binding studies using "NI-labelled LYP8 were performed.
LYP8 binding to M3Da. melanoma cells was specific,
concentration-dependent and saturable with 367 000 +
58 000 (mean ± s.d., n = 3) LYP8 binding sites per cell and a
dissociation constant (Kj) of 67 nM (Figure 2). Binding of
labelled LYP8 to M3Da. cells was reduced by 90% in the
presence of a 100-fold excess of unlabelled TSP. `2I-labeLed
TSP binding to M3Da. cells was concentration dependent
over the range of 0.4 to 24pg 10-' with at saturation
400000 ±50000 TSP binding sites per cell (mean ± s.d.,
n = 3) and a dissociation constant (Kd) of 10 nM. In the
presence of an excess of cold TSP, binding of 'II-labelled
TSP was reduced to less than 85%. LYP8 (lOjgml-') did
not affect the binding of labelled TSP to M3Da. cells or to
platelets stimulated with thrombin (0.4 Uml-') (results not
shown). In human blood platelets and in certain tumour cell
hnes, CD36 was shown to act as one of the TSP receptors
(Asch et al., 1987; McGregor et al., 1989; Silverstein et al.,
1992). These results clearly demonstrate that M3Da_ syn-
thebse and secrete into the culture medium a protein
immunologically related to TSP that binds to the cell surface
via receptors different from CD36.
Inhibition ofplatelet-melanoma interaction by
anti-thrombospondin (TSP) MAb LYP8
Since M3Da. cells synthesis TSP and bind LYP8, the role of
TSP in tumour-platelet interaction was investigated. M3Da.
cells irreversibly aggregated human platelets in heparinised
PRP (Figure 3). Platelets washed by the technique of Mus-
tard et al. (1972) are not aggregated by M3Da_ melanoma
cells (results not shown). Addition to platelets of LYP8
(24pg 10-' cells) inhibited platelet aggregation induced by
M3Da. (Figure 3). If M3Da. cells are preincubated with a
saturating concentration of LYP8 (24pg 10-' cells), washed
three times with HBSS-BSA, then added to platelets, agg-
regation is blocked (Figure 3). Anti-TSP MAbs, LYPIO or
LYP12, used at the same concentration or a non-immune
mouse serum IgG, had no effect on platelet aggregation
induced by melanoma cells. As previously shown, an anti-
cac MAb (LYP18) added to M3Da. cells sign tly
inhibited platelet aggregation induced by M3Da_ cells (Figure
3) (Boukerche et al., 1989a).
Electron microscopy ofmenoma-platelet interactions
Electron microscopy studies showed that melanoma cells
closely interacted with platelets (Figure 4a). Melanoma cells
at the site of their interaction with platelets formed ext-
rusions or processes which penetrated into the platelet agg-
regates (Figure 4b) (Boukerche et al., 1989a). Addition to a
platelet-tumour cell mixture of anti-TSP MAb LYP8
resuled in a signifant decrease in the size of platelet agg-
regates (Figure 4c). Moreover, platelet-melanoma cell
intractions could not be observed, confirming the agg-
regometry results (Figure 4c). Moreover, in the presence of
LYP8, the tumour cell surface did not show cytopLamic
extrusion or processes (Figure 4c).
Effect ofLYP8 on melanoma tumourgrowth in nude mice
The biological role of TSP binding to M3Da. cells was inves-
tigated by implanting subcutaneously the M3Da. cell ie in
nude mice and following the size and time of in vivo tumour
growth over a period of 6 weeks. In the presece of LYP8
(24pg 10- cells), M3Da. cells are inhibited from growing
into full-sized tumours as observed in control animls
(Figure Sa). Similar inhibition was observed with an anti-4aBidolojce role oftlwoniospd hi mnomacdi aiuoacian
H Boukerche et a
111
M3 Dau.
I I
B C D E
- TSP
L~~~~JL-J~~~~~ NI 1R I
NRl R
b Anti-TSP MAb (LYP8) Anti-CD36 MAb Anti-a., R3 MAb (LYP18)
Fugwe 1 (a) Immunoprecipitation by LYP8 monoclonal antibody (MAb) of thrombospondin (TSP) from chase medium of
metabolically labelled 35S]methionine) M3Da (= M3Dau.) human melanoma cells. Immunoprecipitates were applied to 5-15%
exponential gradient SDS-polyacrylamide gels and electrophoresed under non-reducing (NR) or reducing (R) conditions. Lanes A.
chase medium; lanes B and E, immunoprempitates with LYP8 MAb; lanes C and D, immunoprecipitates with non-immune mouse
serum IgG. (b) Immunofluorescence staining of M3Da. human melanoma cells by an anti-TSP MAb LYP8. M3Da. cells were
incubated with LYP8 or an anti ,0 MAb (LYP18) or an anti-CD36 MAb (OKM5). Rabbit anti-mouse IgG F(ab'), antibody
conjugated to fluorescein isothiocyanate (FITC) was then added to cells.
MAb LYP18 (Figure 5a). The inhibition of tumour cell
growth by LYP8 or LYP18 extends over a period of 40 days.
Over that period M3Da. cells gave rise to small tumours
growing at a lower rate than in the controls. Other anti-TSP
MAbs (LYPIO, LYP12, directed respectively against the
70 kDa trypsin-resistant core region and the heparin-binding
domain of TSP) had no effect on tumour growth. Combina-
tion of the two MAbs (LYP8 + LYP18), used at saturating
concentrations, gave similar results as that obtained with
anti-ak MAb LYP18. To rule out the possibility that LYP8
might have a direct cytotoxic effect, melanoma cells were
preincubated with excess LYP8 (241igml-') and monitored
for cell viability and cell growth. No loss of melanoma cells
viability was shown by trypan blue exclusion. Furthermore,
control and LYP8-treated cells showed a similar degree of
[3H]thymidine uptake and cell growth in vitro (Figure 5b and
c). The lack of effect caused by the antimelanoma MAb G7A5
suggests that the observed inhibition by LYP8 or LYP18 in
vivo was not due to complement-dependent cytotoxicity or
opsonisation. Moreover, in the presence of fresh rabbit or
nude mice sera containing complement, LYP8 did not sup-
port lysis of melanoma cells (results not shown). As
previously reported, natural killer cells are not involved in
M3Da. growth in nude mice (Jacubovich et al., 1984).
Adhesion assays
In order to study the mechanism allowing an anti-TSP MAb
(LYP8) to inhibit tumour growth, we looked at the ability of
TSP to support M3Da. adhesion, and the effect of LYP8 on
such an interaction. M3Da. cells attached to TSP-coated wells
with 20% of cells spreading (Figure 6a). LYP8 had no effect
on the attachment of M3Da. cells to TSP but decreased
significantly the number of cells spreading on TSP (Figure 6a
and b). Extending the incubation time of tumour cell
adhesion on TSP with LYP8 from 60 to 90 min gave similar
results (results not shown). TSP secretion does not promote
shedding of antibody since '"I-labelled LYP8 bound to TSP-
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Figwe 2 Binding of '"I-labelled anti-thrombospondin (TSP)
monoclonal antibody (MAb) (LYP8) to M3Da. human melanoma
cells. Huiman melanoma cells grown to confluence in serum-free
RPMI were detached by trypsin-EDTA or EDTA and
resuspended in RPMI-1640 containing 0.35% BSA. Increasing
concentrations of '"I-labelled LYP8 were added and incubated
overnight at 4-C. The insert shows a double-reciprocal plot of the
same data with Kd = 66.6 nM and the maximum number of bind-
ing sites of 4 x 105 per cell. Non-specific binding of labeled
LYP8 was obtained by using a 100-fold excess of unlabeUled
LYP8.
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Fugwe 3 Effect of an anti-thrombospondin (TSP) monoclonal
antibody (MAb) (LYP8) on aggregation of platelets in PRP
induced by M3Da. (= M3Dau.) human melanoma cells. Typical
aggregation curves of platelet in heparinised PRP induced by the
addition of M3Da. melanoma cells (4 x 10'). Controls were either
HBSS-BSA buffer or a non-immune mouse serum IgG. LYP8
(24pg 10-') or LYP18 (14jg 10-') were added to platelets
before the addition of M3Da. melanoma cells. Similar results
were obtained with M3Da. melanoma cells pretreated with LYP8
(24#g 10-6), washed three times with HBSS-BSA, then added to
platelets.
Figwe 4 Ultrastructural analysis of M3Da. human melanoma-
platelet interactions. At the end of the aggregation curve,
platelet-melanoma suspensions were fixed with glutaraldehyde
and prepared for electronmicroscopy as described in Materials
and methods. (a) Platelets aggregates (p) in direct contact with
M3Da. melanoma cells (m) ( x 3400). (b) At higher magnification,
melanoma (m) showed extrusions (arrows) at the site of their
interaction with platelets (p) ( x 12 500). (c) Platelets (p) not
interacting with MPDa. melanoma ceUs (m) when platelets were
preincubated with LYP8 ( x 3400). Bar = 2 gm.
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Figwe 5 (a) Inhibition of melanoma tumour growth in nude
mice by anti-thrombospondin (TSP) monoclonal antibody (MAb)
(LYP8). M3Da. cells (1 x 106) were grafted subcutaneously (s.c.)
on the ventral face of nude mice after preincubation for 10 min
with purified LYP8 (24 #Lg 10-') or anti-cA MAb LYP18
(14 jug 10-6) or a combination of the two MAbs used at
saturating concentration. Controls were non-immune mouse
serum IgG or MAb G7A5 directed against a melanoma cell-
surface antigen. (b) Effect of anti-thrombospondin (TSP) monoc-
lonal antibody (MAb) (LYP8) on in vitro tumour cell prolifera-
tion. (b) M3Da. cells (6.5 x 105 per well) preincubated with a
non-immune mouse serum IgG or MAb LYP8 (24 Mg 10-') were
cultured in RPMI medium containing 10% fetal calf serum. At
selected times, viable tumour cells were counted with a
haemocytometer. Data are the mean of six well counts. (c) Effect
of anti-thrombospondin (TSP) monoclonal antibody (MAb)
LYP8 on in vitro DNA synthesis. M3Da. cells (15 x I03 per well)
preincubated with a non-immune mouse serum IgG or MAb
LYP8 (24 gg 10-') were cultured for 1-2 days in RPMI medium
containing 10% fetal calf serum. The cells were then pulsed with
[3HJthymidine for 12 h. Radioactivity incorporated in the cells
was measured by a standard liquid scintillation counting. Data
are the mean of 12 well counts.
coated wells in the presence of M3Da. cells was not released
into the supernatant (less than 1% of the total TSP bound
LYP8 was recovered in the supematant). Similarly, an anti-
MAb, LYP18, had no effect on attachment but inhibited
spreading of M3Da. cells on TSP (Figure 6b). To examine
further the specificity of TSP binding to mA, an ELISA was
performed. Preliminary experiments performed with Triton
X-100 melanoma cell lysate using LYP18 and LYP8 in a
double-antibody sandwich ELISA showed that TSP binds to
(results not shown). Further experiments were then per-
formed with purified mA. Purified mA was added to wells of
the microtitre plate followed by the addition of increasing
concentrations of TSP or albumin. Binding of TSP to mA
T
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Fgwe 6 (a) Phase-contrast photomicrographs of M3Da. cell
attachment and spreading on TSP in the presence of anti-TSP
monoclonal antibody (MAb) LYP8. Wells were coated with TSP
(2-3jg) and adhesion assays were performed as described in
Materials and methods in the presence of MAb LYP8 or a
control non-immune mouse serum IgG. Cells were fixed with
glutaraldehyde and photographed at a final magnification of
100 x Cells spread on TSP are indicated by arrows. (b) Effect of
anti-thrombospondin (TSP) monoclonal antibody (MAb) (LYP8)
or anti-aA MAb (LYP18) on M3Da. spreading on TSP. Cells
fLxed with glutaraldehyde and counted microscopically. Data are
expressed as the mean ± s.d., n = 3.
bound to LYP18 was significant compared with albumin
(Figure 7). These results show that TSP in M3Da. interacts
with aJ3 receptors and exclude the possibility that the
observed binding may be due to minor contaminants present
in the sample.
This study indicates that one of the adhesive ligands playing
a key role in human melanoma (M3Da.) cell interaction with
platelets is thrombospondin (TSP). Moreover, TSP also
appears to play a crucial role in the control of M3Da. tumour
growth. The site on TSP to which monoclonal antibody
(MAb) LYP8 is directed appears, in contrast to other anti-
TSP MAb's (LYPIO, LYP12) binding to different epitopes,
to play an important role in melanoma-platelet interaction
and tumour growth. Several lines of evidence back the above
statements:
(1) TSP binds with a high affinity to the surface of M3Da.
via receptors that differ from CD36, not expressed by
M3Da.
a
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Fge 7 ELISA detection of thrombospondin (TSP)-J3 com-
plex formation. Purfied (1 -2 pg) was coated on the wells as
described in Materials and Aftr incubain and
washing, ira nn ca nntraiom of TSP or albumin
(0.1-1.5 pg) were aided to the wek and bound TSP was probed
wnth anti-TSP poalyoa antibody followed by borasdish
peroxidase conjugated to goat anti-rabbit antibody. Binding of
anti-TS polydonal antibody was quantified by the additio of
the substrate orthophenyliethylamine. Data are the mean of
three permnts.
(2) Reducing the availability or functional level of TSP by
using an anti-TSP MAb (LYP8) resulted in a nt
decrease of platelet aggregates interacting with
melanoma.
(3) Tumour formation in vivo was also affected by the
presnce of bound LYP8.
(4) LYP8 and an anti (LYP18) inhihited in a similar
way sding of M3Da cells to coated TSP.
(5) Purified binds TSP in an ELISA.
An important point to be added to the above obsrvations
is that Nake- platelets deficint in CD36 have been shown to
aggregate normally in the presence of M31Da meanoma cells
(H Boukerhe, B Kehrel and JL McGregor, unpublished
obsevations) (Kehrel et al., 1993). The absenc of CD36
expression on M3Da suggts that TSP binds to this
melanoma cell line via another Leceptor. An obvious can-
didate to bind TSP could bet3, which is known to bind to
the RGDA sequence of TSP on endothelial and melanoma
ceIls (Lawler et al., 1988; Tuszynsi et al., 1989). This recep-
tor (4A1) has been shown to be expssed by M3Da and
plays, as previously indicated, a crucial role in
melanoma-platelet interacion and in vivo melanoma tumour
growth (Boukerche et al., 1989a,b; Marshal et al., 1991;
Felding-Habermann et al., 1992). Reults in this study and
previous work (Lawler et al., 1988; Tuszynski et al., 1989)
sugget that TSP binding to a.$-1, expeSSed by M3Da, is
directly impliated in melanoma-platelet intraction and
tumour growth formation in vivo. Our data do not exdude a
possible role of CD36 present in the microenvironment of a
tumour in vivo. Results in this study extend observations
made by Tuszynski et al. (1987, 1992), who showed that
whole TSP and a peptide (CSVTCG) derived from this
adhesive ligand affect tumour metastasis of mouse
melanoma. Moreover, CSVTCG and its analogue have been
shown to be potent inhibitors of platelet aggregation (Byck
and McGregor, 1992). The recent discovery of four
homologous forms of TSP (TSP-i, TSP-2, TSP-3 and TSP-4)
encoded by distinct genes indicates that further characterisa-
tion of TSP expressed by melanomas is required (Bonstein,
1992).
An anti-TSP MAb (LYP8) signntly affects platelet agg-
regates intacting with melanoma cells, as shown in the
electrn micrograph presented in this study. However, LYP8
did not reduc TSP binding to M3Da. cells, nor did it affect
TSP binding to washed platelets stimulated with thrombin.
These results indicate that LYP8 may interfere by steric
hindrance with a mechanism involved in linking tumour cells
and platelets together and suggest that TSP coating M3Da.
cells is dirtly involved in mediating tumour cell-platelet
interactions. A similar observation was reported with LYP8
and other MAbs dircted against GPIIb and lIla, which
together inhibited platelet aggregation without affecting
fibrinogen binding (Newman et al., 1987; Boukerche and
McGregor, 1988). These results suggest that additional post-
TSP binding events such as conformational changes and/or
clustering of cell-surface moleules may be required to sup-
port tumour-platelet interaction (Peerschke and Zucker,
1981).
Such a role of TSP in mediating cell-cell interactions was
also shown with thrombin-activated platelets binding to a
monocytic cell line (U937) or to melanoma cells (Nierodzik
et al., 1991; Silverstein et al., 1992). In contrast to these
findings, platelets in our system are activated by ADP and
released by M3Da. cells, under conditions in which
presumably no secretion from platelets takes place (Bouker-
che et al., 1989a). Recent results from our laboratory indicate
that ADP is present in appreciable amounts (180 ±10 pmol
10-6 cels) in thecell supernatant of M3Da.cells as shown by
high-performance liquid chromatography (HPLC) (Boulker-
che et al., 1994). Previous observations have shown that
platelets activated by ADP in the presence of physiological
levels of Ca2", as present in heparinised PRP, aggregate but
do not release their a-granule content (Mustard et al., 1972).
Under these conditons, TSP relased by M3Da. cells will not
bind to platelets that have not undergone release (Leung,
1984; Boukerche and McGregor, 1988). In view of these
results, it appears that ADP-activated platelets need to
interact with melanoma cell-surface receptors presumably via
amA3 to undergo complete degranulation as observed in
electron-micrgrphs obtained in this study and in a
previous work (Boukerche et al., 1989a). Platelet-melanoma
interactions may therefore be initiated by: (1) the release of
ADP by M3Da cells and (2) mehanial stimulation induced
by the M3Da. cell surface. Melanoma cells, by interacting
with the platelet surface, may promote agonist and ADP
rekase from platekts, leading to degranulation and forma-
tion of larger platelet-tumour aggregates. TSP coating of
degranulated platelet is known to help in cmenting platelet
aggregates (Leung, 1984, Boukerche and McGregor, 1988).
The ability of tumour cells to induce platelet activation in
vitro has been used as indirect evidence to show the role of
platelets in the diinaton of tumour cells (Gasic et al.,
1973). TSP linking the tumour-platelet aggregates may pro-
vide a vehicle for tansport and diination of tumour
cells. Experiments are under way to determine the metastatic
capacity of M3Da. binding TSP.
Tumour growth is the result of a complex interaction
between tumour cells and the basement membrane extracel-
lular matrix components (Dvorak et al., 1991). TSP appears
to play a crucial role in the control of tumour growth. The
finding that anti-TSP MAb LYP8 did not completely inhibit
tumour growth suggst that other glycopotein receptors
and adhesive proteins contribute to the full expesson of the
tumorigenic phenotype of the cells. Adhesive proteins such as
TSP binding to melanoma cells may in vivo modulate cellular
proliferation as previously shown for normal and trans-
formed cells (Majack et al., 1988; Abbadia et al., 1993).
Alternatively, MAb LYP8 binding to TSP may block critical
interactions between melanoma cells and stromal matrices
that are vital for successful angiogenesis (Tolsma et al., 1993;
Dameron et al., 1994).
TSP is a multidomain glycoprotein that binds to a number
of adhesive ptors (Asch et al., 1987; Lawler et al., 1988;
Roberts, 1988; Karczewski et al., 1989 McGregor et a!.,
1989; Yabkowitz an Dixit, 1991). One of its receptors,
CD36, which binds to the 68 kDA TSP fragment via the type
I rpeat (CSVTCG) in the absnce of Ca2 +,isnot exrs
by M3Da. cels(Asch et at, 1992;Catimel et al, 1992). In the
current study, M3Da. cells that lack CD36
attacd and spread on TSP in a similar way as reported by
Roberts et al(1987) for melanoma G361. LYP8and LYP18
MAbs inhibited M3Da. spreading on TSP. Purified a,3was
shown to bind TSP. These results and previous work (LawlerBi.aIirole of a
urospnmin_mlonacd iuiraclis
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et al., 1988; Tuszynski et al., 1989) suggest that TSP interacts
with mA. Inhibition by LYP8 of TSP-mediated M3Da.
spreading and melanoma-platelet interaction could be the
result, as previously suggested in this study, of steric or
conformational changes of TSP induced by LYP8 (Dixit et
al., 1986). Our data do not exclude the possibility that, in
addition to aCm, TSP may bind to other receptors (i.e.
heparan sulphate proteoglycans) in view of the lack of effect
of LYP8 in inhibiting cell attachment of M3Da. to TSP-
coated wells (Roberts, 1988; Asch et al., 1991).
Our results are consistent with recent studies of Castle et
al. (1991) showing the importance of TSP by transfecting
human squamous carcinoma cells with the TSP cDNA
antisense expression vector and decreasing the tumorigenic
phenotype of these cells. Moreover, the CSVTCG TSP pep-
tide and its analogue was shown to block cell adhesion,
platelet aggregation and tumour cell metastasis (Tuszynski et
al., 1992; Byck and McGregor, 1992). Tumour metastasis is a
complex sequence ofevents in which malignant cells enter the
bloodstream and interact with various host cells, including
vascular endothelial cells, before extravasating and forming
secondary tumours (Nicolson, 1988). Reagents such as MAbs
against TSP and peptides derived from TSP could not only
be used as a new therapeutic approach in the control of
tumour metastasis of malignant melanoma, but may also
contribute to the elucidation on the role of TSP in cancer
biology.
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